Dogwood Therapeutics, Inc(DWTX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Dogwood Therapeutics Reports Third Quarter 2025 Financial Results - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction - ATLANTA, Ga., November 6, 2025 -- Dogwood Therapeuti ...